Article
Gastroenterology & Hepatology
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Summary: This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients. The results showed that HBV-associated DLBCL patients receiving antiviral treatment had significantly longer time-to-progression and overall survival after R-CHOP treatment.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Cell Biology
Xiaofei Ye, Lei Wang, Man Nie, Yuyao Wang, Shichen Dong, Weicheng Ren, Guibo Li, Zhi-Ming Li, Kui Wu, Qiang Pan-Hammarstrom
Summary: This study analyzes the transcriptomes of DLBCL cells using single-cell RNA sequencing and reveals high intra- and inter-tumor heterogeneity. The study also predicts cell-cell interactions and the complex tumor microenvironment. Additionally, the study identifies important cell interactions and suggests that chronic hepatitis B virus infection may impact DLBCL treatment and immune evasion.
Article
Hematology
Marcella Visentini, Andrea Pica, Giancarlo D'Ippolito, Eleonora Sculco, Francesca La Gualana, Laura Gragnani, Marzia Miglionico, Cesare Mazzaro, Massimo Fiorilli, Stefania Basili, Maurizio Martelli, Alice Di Rocco, Milvia Casato, Giuseppe Gentile, Alessandro Pulsoni
Summary: Studies suggest that both active and past hepatitis B virus (HBV) infection may increase the risk of developing diffuse large B-cell lymphoma (DLBCL) in low endemic areas. This conclusion is based on a retrospective review of clinical records in Italy, involving 253 DLBCL patients and 694 patients with different types of indolent B-cell non-Hodgkin's lymphoma (NHL). The study found that DLBCL patients had a higher prevalence of both active HBV infection and past infection compared to indolent NHL patients. These findings highlight the importance of further research in areas with different rates of HBV infection.
ANNALS OF HEMATOLOGY
(2023)
Article
Health Care Sciences & Services
Yu-Fen Tsai, Yi-Chang Liu, Ching- Yang, Tzer-Ming Chuang, Ya-Lun Ke, Tsung-Jang Yeh, Yuh-Ching Gau, Jeng-Shiun Du, Hui-Ching Wang, Shih-Feng Cho, Chin-Mu Hsu, Pey-Fang Wu, Ching- Huang, Chung-Feng Huang, Ming-Lung Yu, Chia-Yen Dai, Hui-Hua Hsiao
Summary: HCV-positive DLBCL patients show poorer performance status, higher complication rates, and intolerance to treatment, leading to fewer treatment cycles and inferior survival outcomes.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Immunology
Shidai Mu, Deyao Shi, Lisha Ai, Fengjuan Fan, Fei Peng, Chunyan Sun, Yu Hu
Summary: The study revealed that the IPI-IPM has independent prognostic significance for DLBCL patients, showing that high-risk patients had worse overall survival and were correlated with immune-related signaling pathways, high mutation rates, and upregulation of inhibitory immune checkpoints, suggesting a greater potential response to ICB therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Shunfeng Hu, Na Chen, Kang Lu, Changqing Zhen, Xiaohui Sui, Xiaosheng Fang, Ying Li, Yingshu Luo, Xiangxiang Zhou, Xin Wang
Summary: This study identified a close association between HBV antibody and clinical prognosis in DLBCL patients, providing a potential biomarker for predicting the effect of Rituximab and prognosis in DLBCL patients.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Zhongqi Li, Fang Yu, Wenle Ye, Liping Mao, Jiansong Huang, Yang Shao, Junrong Yan, Wenjuan Yu, Jie Jin, Jinghan Wang
Summary: NOTCH1 mutations in DLBCL patients are associated with poor prognosis and can serve as an independent predictor.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Shu-Yun Ma, Xiao-Peng Tian, Jun Cai, Ning Su, Yu Fang, Yu-Chen Zhang, Jin-Ni Wang, Robert Peter Gale, Qing-Qing Cai
Summary: A prognostic score for DLBCL patients based on infiltrating immune cells was constructed, showing that the immune risk score is an accurate and independent survival predictor in DLBCL patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Surgery
Zhuoya Zhou, Jing Chen
Summary: This study is the largest population-based study to date on independent prognostic factors of CCSV-DLBCL. Age, race, surgical resection, radiation, and chemotherapy are closely associated with patients' survival outcomes.
ASIAN JOURNAL OF SURGERY
(2023)
Article
Oncology
Eugene Kim, Yanwen Jiang, Tao Xu, Alexandra Bazeos, Andrea Knapp, Christopher R. Bolen, Kathryn Humphrey, Tina G. Nielsen, Elicia Penuel, Joseph N. Paulson
Summary: This study applied non-negative matrix factorization (NMF) and targeted sequencing data to analyze DLBCL, and found that different mutation clusters are associated with clinical prognosis. Specifically, improved overall survival was observed in the BCL2/EZH2 group, which received venetoclax therapy.
Review
Biochemistry & Molecular Biology
Xiao-jie Liang, Xin-yu Song, Jia-lin Wu, Dan Liu, Bing-yu Lin, Hong-sheng Zhou, Liang Wang
Summary: This article provides an overview of the research advances in DLBCL prognostic biomarkers using a multi-omics approach. It emphasizes the urgent need for highly specific and sensitive biomarkers to predict the therapeutic response of DLBCL and assess patient benefit from systemic chemotherapy. The use of systems biology in DLBCL research is highlighted for its comprehensive quantification and identification of biomarkers and its potential to address major biological problems with high accuracy and sensitivity.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Endocrinology & Metabolism
Jiaqin Yan, Wei Yuan, Junhui Zhang, Ling Li, Lei Zhang, Xudong Zhang, Mingzhi Zhang
Summary: In this study, we established a prognostic prediction model with eight genes that can effectively predict the survival outcomes of DLBCL patients. We also created a nomogram to visualize the prediction model and explored immune alterations between high- and low-risk groups.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Reyizha Nuersulitan, Miaomiao Li, Lan Mi, Meng Wu, Xinqiang Ji, Yiqi Liu, Hong Zhao, Guiqiang Wang, Yuqin Song, Jun Zhu, Weiping Liu
Summary: In patients with diffuse large B-cell lymphoma and Hepatitis B virus (HBV) infection, the prognosis is not negatively affected by HBV. Immune-chemotherapy and prophylactic antiviral therapy showed good efficacy and survival outcomes, with a high response rate and complete remission rate.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Marjukka Pollari, Suvi-Katri Leivonen, Sirpa Leppa
Summary: Testicular diffuse large B-cell lymphoma (T-DLBCL) is a rare and aggressive lymphoma that mainly affects elderly men, with a high relapse rate. It presents in an immune-privileged site of the testis, with unique biology and immune-related characteristics. Studies on the tumor microenvironment and immune checkpoint inhibitors show promising results for the treatment of T-DLBCL.
Review
Medicine, General & Internal
Jose Manuel Martin de Bustamante, Ana Mendoza, Samuel Lopez-Munoz, Eugenia Garcia-Fernandez, Pilar Gomez-Prieto, Victor Jimenez-Yuste
Summary: Recently, a new lymphoproliferative entity called breast implant-associated Epstein-Barr virus positive (EBV+) diffuse large B-cell lymphoma (EBV+ BIA-DLBCL) has been reported. The World Health Organization has categorized it as fibrin-associated large B-cell lymphomas (FA-LBCLs), thus it can be referred to as breast implant-associated fibrin-associated large B-cell lymphomas (BIA-FA-LBCLs). While the association between breast implants and lymphomas has been known for a long time, it has mostly been focused on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This article describes the first case of BIA-FA-LBCL at a particular center, provides a literature review on its clinical features, diagnosis, and treatment approach, as well as explores the challenges in differential diagnosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Genetics & Heredity
Wu Jiang, Lin Li, Chuan-Feng Ke, Wei Wang, Bin-Yi Xiao, Ling-Heng Kong, Jing-Hua Tang, Yuan Li, Xiao-Dan Wu, Ying Hu, Wei-Hua Guo, Si-Zhen Wang, De-Sen Wan, Rui-Hua Xu, Zhi-Zhong Pan, Pei-Rong Ding
Summary: This study found that universal germline testing in patients with colorectal cancer can help identify potential hereditary cancer syndromes, especially in those under 70 years old. Enhanced surveillance and tailored treatment may be beneficial for patients with germline pathogenic variants.
JOURNAL OF MEDICAL GENETICS
(2022)
Article
Multidisciplinary Sciences
Christophe Glorieux, Xiaojun Xia, Xin You, Zining Wang, Yi Han, Jing Yang, Gauthier Noppe, Christophe de Meester, Jianhua Ling, Annie Robert, Hui Zhang, Sheng-Ping Li, Huamin Wang, Paul J. Chiao, Li Zhang, Xiaobing Li, Peng Huang
Summary: This study investigated the impact of two common chemotherapy drugs, gemcitabine and cisplatin, on the therapeutic efficacy of PD-1 antibody in K-ras-driven cancers. The results showed that gemcitabine inhibits CD8+ T cell infiltration and antagonizes the therapeutic effect of PD-1 antibody, while cisplatin activates CD8+ T cells and shows synergistic activity with PD-1 antibody. Clinical data suggests that the combination of cisplatin and PD-1 antibody may be effective in advanced lung cancer patients with K-ras mutation.
JOURNAL OF ADVANCED RESEARCH
(2022)
Editorial Material
Oncology
Long Bai, Xiao-Luan Yan, Yun-Xin Lu, Qi Meng, Yu-Ming Rong, Liu-Fang Ye, Zhi-Zhong Pan, Bao-Cai Xing, De-Shen Wang
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Engineering, Chemical
Yeping Xie, Liufang Ye, Wenhua Chen, Pengju Liu, Yuansen Liu
Summary: This study demonstrates a method to convert waste cross-linked polyethylene (CLPE) cables into low-cost, high-strength, and all-weather electromagnetic interference (EMI) shielding materials. By utilizing selective heating mode of microwave and remaining cross-linked structure, a segregated structure with carbon nanotubes (CNTs) selectively enriched at the interfaces of the CLPE phases was successfully constructed, improving the electrical and EMI shielding properties of the composite material and exhibiting stable performance.
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
(2022)
Article
Multidisciplinary Sciences
Qi Zhao, Feng Wang, Yan-Xing Chen, Shifu Chen, Yi-Chen Yao, Zhao-Lei Zeng, Teng-Jia Jiang, Ying-Nan Wang, Chen-Yi Wu, Ying Jing, You-Sheng Huang, Jing Zhang, Zi-Xian Wang, Ming-Ming He, Heng-Ying Pu, Zong-Jiong Mai, Qi-Nian Wu, Renwen Long, Xiaoni Zhang, Tanxiao Huang, Mingyan Xu, Miao-Zheng Qiu, Hui-Yan Luo, Yu-Hong Li, Dong-Shen Zhang, Wei-Hua Jia, Gong Chen, Pei-Rong Ding, Li-Ren Li, Zheng-Hai Lu, Zhi-Zhong Pan, Rui-Hua Xu
Summary: Through ultradeep whole-exome sequencing, we identified 46 significantly mutated genes associated with CRC and proposed a subtyping strategy that classifies CRC patients into four genomic subtypes with distinct clinical characteristics. Additionally, we found that mitochondrial DNA copy number is an independent factor for predicting the survival outcome of CRCs.
NATURE COMMUNICATIONS
(2022)
Article
Genetics & Heredity
Zhen Zhang, Zi-Xian Wang, Yan-Xing Chen, Hao-Xiang Wu, Ling Yin, Qi Zhao, Hui-Yan Luo, Zhao-Lei Zeng, Miao-Zhen Qiu, Rui-Hua Xu
Summary: By analyzing single-cell RNA sequencing data from ICI-treated patients, it was found that cancer stemness may be associated with resistance to ICI treatment. The developed novel stemness signature (Stem.Sig) showed improved predictive performance for ICI response across multiple cancers, potentially serving as a competitive tool for patient selection in immunotherapy.
Article
Oncology
Jia Bo Zheng, Chau Wei Wong, Jia Liu, Xiao-Jing Luo, Wei-Yi Zhou, Yan-Xing Chen, Hui-Yan Luo, Zhao-Lei Zeng, Chao Ren, Xiao-Ming Xie, De-Shen Wang
Summary: PFKFB3 inhibition suppresses tumor growth in vitro and in vivo, but induces upregulation of PD-L1 levels, compromising anti-tumor immunity and reducing efficacy.
Article
Gastroenterology & Hepatology
Ting Li, Yue-Tao Tan, Yan-Xing Chen, Xiao-Jun Zheng, Wen Wang, Kun Liao, Hai-Yu Mo, Junzhong Lin, Wei Yang, Hai-Long Piao, Rui-Hua Xu, Huai-Qiang Ju
Summary: Methionine and YTHDF1 play a critical role in anticancer immunity through regulating the functions of T cells. Targeting methionine metabolism or YTHDF1 could be a potential new strategy for cancer immunotherapy.
Letter
Oncology
Rui Liu, Panpan Liu, Huichang Bi, Jianhua Ling, Huiqin Zhang, Mingquan Zhang, Yumin Hu, Paul J. Chiao, Peng Huang, Jinyun Liu
CANCER COMMUNICATIONS
(2023)
Article
Oncology
Xiao-Li Wei, Yang Zhang, Hong-Yun Zhao, Wen-Feng Fang, Hui-Yan Luo, Miao-Zhen Qiu, Ming-Ming He, Ben-Yan Zou, Jie Xie, Chun-Lei Jin, Xian-Feng Zhou, Feng Wang, Feng-Hua Wang, Yu-Hong Li, Zhi-Qiang Wang, Rui-Hua Xu
Summary: This report presents the results of two phase I trials evaluating the tolerability, safety, and preliminary antitumor activity of SHR7390 monotherapy and SHR7390 in combination with camrelizumab in patients with advanced solid tumors and treatment-refractory advanced or metastatic colorectal cancer (CRC).
Retraction
Cell Biology
Hong-En Yu, Feng Wang, Fang Yu, Zhao-Lei Zeng, Yun Wang, Yun-Xin Lu, Ying Jin, De-Shen Wang, Miao-Zhen Qiu, Heng-Ying Pu, Tie-Bang Kang, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu, Hui-Yan Luo
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Yi Han, Yan-Yu Zhang, Yi-Qian Pan, Xiao-Jun Zheng, Kun Liao, Hai-Yu Mo, Hui Sheng, Qi-Nian Wu, Ze-Xian Liu, Zhao-Lei Zeng, Wei Yang, Shu-Qiang Yuan, Peng Huang, Huai-Qiang Ju, Rui-Hua Xu
Summary: Interleukin-10 (IL-10) plays a role in inflammation and tumor progression, but its role in cancer is unclear. This study found that IL-10 stimulation leads to acetylation of nicotin-amide nucleotide transhydrogenase (NNT) in cancer cells, which induces the translocation of p300/CBP-associated factor (PCAF) to the mitochondria. This acetylation enhances NNT activity, increases NADPH production, and protects tumor cells from ferroptosis, contributing to tumor immune evasion.
Article
Oncology
Zeyi Guo, Qingyu Xie, Yanping Wu, Haiyu Mo, Jiajun Zhang, Guolin He, Zhongzhe Li, Luxiang Gan, Lei Feng, Ting Li, Yi Wang, Yu Fu, Lei Cai, Shao Li, Chao Yu, Yi Gao, Mingxin Pan, Shunjun Fu
Summary: This study reveals the role of a circular RNA molecule, circDHPR, in hepatocellular carcinoma (HCC). It affects tumor growth and metastasis by regulating the miR-3194-5p/RASGEF1B/Ras/MAPK signaling pathway, suggesting circDHPR as a potential biomarker and therapeutic target for HCC.
Proceedings Paper
Computer Science, Artificial Intelligence
Chunlei Cai, Yi Wang, Xiaobo Li, Tianxiao Ye
Summary: This paper proposes a novel deep learning based two-pass encoder parameter prediction framework, which can provide video streams with constant quality. The experimental results show high accuracy and low encoding complexity of the proposed method.
2022 IEEE INTERNATIONAL CONFERENCE ON VISUAL COMMUNICATIONS AND IMAGE PROCESSING (VCIP)
(2022)
Article
Biochemistry & Molecular Biology
Jin-Fei Lin, Pei-Shan Hu, Yi-Yu Wang, Yue-Tao Tan, Kai Yu, Kun Liao, Qi-Nian Wu, Ting Li, Qi Meng, Jun-Zhong Lin, Ze-Xian Liu, Heng-Ying Pu, Huai-Qiang Ju, Rui-Hua Xu, Miao-Zhen Qiu
Summary: This study reveals the role and regulation mechanism of cysteine desulfurase (NFS1) in the sensitivity of colorectal cancer cells to oxaliplatin. Loss of NFS1 enhances the sensitivity of colorectal cancer cells to oxaliplatin and triggers PANoptosis by increasing intracellular levels of reactive oxygen species (ROS). In addition, high expression of NFS1 is associated with poor survival and chemoresistance in patients with colorectal cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)